[1] Qu X, Zhai Y, Wei H, et al. Characterization and expression of three novel differentiationrelated genes belong to the human NDRG gene family[J]. Mol Cell Biochem, 2002, 229(1/2): 35-44.
[2] Deng Y, Yao L, Chau L, et al. NMyc downstreamregulated gene 2 (NDRG2) inhibits glioblastoma cell proliferation[J]. Int J Cancer, 2003, 106(3): 342-347. DOI: 10.1002/ijc.11228.
[3] Choi SC, Kim KD, Kim JT, et al. Expression and regulation of NDRG2 (Nmyc downstream regulated gene 2) during the differentiation of dendritic cells[J]. FEBS Lett, 2003, 553(3): 413-418.
[4] Lorentzen A, Vogel LK, Lewinsky RH, et al. Expression of NDRG2 is downregulated in highrisk adenomas and colorectal carcinoma[J]. BMC Cancer, 2007, 7: 192. DOI: 10.1186/1471-2407-7-192.
[5] Zhao H, Zhang J, Lu J, et al. Reduced expression of NMyc downstreamregulated gene 2 in human thyroid cancer[J]. BMC Cancer, 2008, 8: 303. DOI: 10.1186/1471-2407-8-303.
[6] Kim HS, Kim MJ, Lim J, et al. NDRG2 overexpression enhances glucose deprivationmediated apoptosis in breast cancer cells via inhibition of the LKB1AMPK pathway[J]. Genes Cancer, 2014, 5(5/6): 175185.
[7] Chu D, Zhang Z, Li Y, et al. Prediction of colorectal cancer relapse and prognosis by tissue mRNA levels of NDRG2[J]. Mol Cancer Ther, 2011, 10(1): 47-56. DOI: 10.1158/1535-7163.MCT-10-0614.
[8] Johnson JL, Baker AH, Oka K, et al. Suppression of atherosclerotic plaque progression and instability by tissue inhibitor of metalloproteinase2: involvement of macrophage migration and apoptosis[J]. Circulation, 2006, 113(20): 2435-2444. DOI: 10.1161/CIRCULATIONAHA.106.613281.
[9] Lewandowski KC, Komorowski J, Mikhalidis DP, et al. Effects of hormone replacement therapy type and route of administration on plasma matrix metalloproteinases and their tissue inhibitors in postmenopausal women[J]. J Clin Endocrinol Metab, 2006, 91(8): 3123-3130. DOI: 10.1210/jc.20052789.
[10] Shen L, Qu X, Ma Y, et al. Tumor suppressor NDRG2 tips the balance of oncogenic TGFβ via EMT inhibition in colorectal cancer[J]. Oncogenesis, 2014, 3(2): e86. DOI: 10.1038/oncsis.2013.48.
[11] Yang J, Zheng J, Wu L, et al. NDRG2 ameliorates hepatic fibrosis by inhibiting the TGFβ1/Smad pathway and altering the MMP2/TIMP2 ratio in rats[J]. PLoS One, 2011, 6(11): e27710. DOI: 10.1371/journal.pone.0027710.
[12] Kim A, Kim MJ, Yang Y, et al. Suppression of NFkappaB activity by NDRG2 expression attenuates the invasive potential of highly malignant tumor cells[J]. Carcinogenesis, 2009, 30(6): 927-936. DOI: 10.1093/carcin/bgp072.
[13] Golestan A, Mojtahedi Z, Ghalamfarsa G, et al. The effects of NDRG2 overexpression on cell proliferation and invasiveness of SW48 colorectal cancer cell line[J]. Iran J Med Sci, 2015, 40(5): 430-439.
[14] Lee DG, Lee SH, Kim JS, et al. Loss of NDRG2 promotes epithelialmesenchymal transition of gallbladder carcinoma cells through MMP19mediated Slug expression[J]. J Hepatol, 2015, 63(6): 1429-1439. DOI: 10.1016/j.jhep.2015.08.007.
[15] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262. |